T he introduction of chlorpromazine in the early 1950s heralded a new era in the treatment of schizophrenia, establishing antipsychotics as the cornerstone of treatment programs. Numerous antipsychotics were developed thereafter, and collectively they demonstrated a substantial impact on psychotic or the so-called positive symptoms of schizophrenia (that is, delusions and hallucinations). However, the benefit bestowed by these typical antipsychotics or FGAs was tempered by high rates of adverse neurologic effects, including parkinsonism and tardive dyskinesia (TD). Clozapine, the prototype of atypical antipsychotics or SGAs, marked a significant advance with its unique pharmacological profile, that is, low dopamine receptor, subtype 2, affinity, and documented efficacy of decreased neurologic side effects and greater efficacy in treatment-refractory populations. 1 Development of numerous SGAs followed thereafter, with claims that they mirrored clozapine's clinical superiority and reduced risk of movement disorders. However, this position has subsequently been challenged based on methodological issues; for example, dosing, related to studies comparing these drugs to FGAs, in addition to a growing body of evidence, indicating that, even among the SGAs, clozapine remained unique in its clinical superiority with the refractory population. 2, 3 As is customary, the initial studies represented efficacy trial; that is, shorter-term RCTs, the standard for regulatory approval. These trials have since given way to 2 large independent effectiveness trials: the United Kingdom's CUtLASS, and the NIMH-initiated CATIE schizophrenia trial. The aim of these 2 investigations was to evaluate the effectiveness of antipsychotics in an environment that mimics the real world in which such patients are treated. This broader net allows inclusion of patients more in line with those seen in routine clinical practice, circumventing the numerous exclusionary criteria that characterize efficacy trials. In the ensuing article, we review the rationale and methodology of these studies, as well as their findings, concluding with a commentary on their relevance to the everyday treatment of people with schizophrenia.
The CUtLASS

Rationale
In an effort to examine the clinical effectiveness of SGAs, a large-scale longitudinal clinical trial that mimicked clinical practice was carried out comparing SGAs and FGAs, 4 and clozapine with other SGAs. 5 The primary goal was to determine if the additional costs of SGAs over FGAs would be offset by improvements in health-related quality of life or savings in the use of other health and social care services in people with schizophrenia for whom a change in drug treatment was considered for clinical reasons. In comparing clozapine to other SGAs, the goal was to clarify the role of these antipsychotic medications in the treatment of people with schizophrenia unresponsive to prior treatments. Of note, the objective was to evaluate the clinical effectiveness of the 2 classes of medications rather than individual drugs. The hypothesis was that use of SGAs would result in clinically significant improvement in quality of life across 1 year, compared with use of FGAs. Further, it was hypothesized that clozapine would be associated with enhanced quality of life over 1 year, compared with other SGAs, along with symptom improvement, increased patient satisfaction, and lower total health care costs.
Design and Methodology
The CUtLASS was a multicentre, rater-blinded RCT, including people from 14 National Health Service Trusts in England. Inclusion criteria included: a DSM-IV diagnosis of schizophrenia, schizoaffective disorder, or delusional disorder; aged 18 to 65 years; at least 1 month since the first onset of psychotic symptoms; and, a psychiatrist electing to change the current antipsychotic treatment owing to inadequate clinical response or intolerance. Exclusion criteria were substance misuse, a medical disorder considered clinically to be the major cause of psychotic symptoms, or a history of neuroleptic malignant syndrome.
The primary outcome measure was total score on the QLS, a widely used instrument in schizophrenia trials, assessed by blinded raters. However, subscales of the QLS were not evaluated. Secondary outcome measures included: PANSS score; Calgary Depression Scale score; Drug Attitudes Inventory and a 7-point drug adherence scale; GAF score; scores on adverse effects rating scales (Simpson-Angus Rating Scale for EPSs, Barnes Akathisia Scale, AIMS for tardive dyskinesia, and the Antipsychotic Non-Neurological Side-Effects Rating Scale); and, participant satisfaction ratings. As part of a cost-effectiveness analysis, cost CUtLASS 2 5 also required that patients be treatment resistant (that is, trials of at least 2 previous antipsychotics with poor clinical response) and considering clozapine as a treatment option. These patients were randomized to receive either clozapine or a nonclozapine SGA (amisulpiride, olanzapine, quetiapine, risperidone, or zotepine). Patients randomized to clozapine required inpatient admission and baseline hematology. For patients randomized to a nonclozapine SGA, the responsible psychiatrist chose one of the available antipsychotics from within that class.
For both CUtLASS 1 and 2 trials, following randomization, psychiatrists were urged to initiate treatment as soon as possible, and keep patients in their randomized treatment arm for a minimum of 12 weeks, preferably for 52 weeks. If treatment change was necessary, the psychiatrist was instructed to initiate an alternative within the same class of medications. Adjunctive medication was permitted, although antipsychotic polypharmacy was discouraged.
Funding
The CUtLASS trials were funded by the Health Technology Assessment Program of the United Kingdom National Health Service. In addition, some authors received support from the Stanley Medical Research Institute. There was no support or funding from the pharmaceutical industry.
Primary Outcomes
The CUtLASS 1 study enrolled a total of 227 patients, with 118 randomized to treatment with an FGA, and the remaining 109 with an SGA. Before randomization, FGAs were prescribed to 207 patients, SGAs to 44 patients, and 28 patients were receiving more than 1 antipsychotic. There were slightly more patients receiving depot FGAs, who were subsequently randomized to the FGA arm, than the SGA arm (44% and 37%, respectively). At 12 months, 185 patients (81%) were still enrolled in the study, with 100 subjects in the FGA arm, and 85 in the SGA arm. Similar numbers of patients in each treatment arm were treated with depot FGAs at 1 year (18% in the FGA arm and 20% in the SGA arm). Analysis of QLS scores for each arm was carried out in an intention-to-treat manner, which included patients in the treatment arms to which they were initially randomized. In addition, a perprotocol analysis was conducted, where participants who switched from their allocated treatment arm were excluded from the analysis.
In surprising contrast to the study's a priori hypothesis, there was no significant difference in QLS scores for people treated with FGAs or SGAs. 4 Rather, there seemed to be an effect in the opposite direction, suggesting a more favourable outcome for patients randomized to treatment with an FGA, although this did not reach statistical significance. This result was consistent in both the intention-to-treat and per-protocol analyses, as well as after-efforts to account for missing data. While the impact of improved treatment adherence owing to treatment with depot FGAs was not specifically examined, it was felt that any beneficial contribution of depot formulations would have needed to be unrealistically large to have generated the study's results.
In CUtLASS 2 there was a total of 136 patients enrolled, with 67 randomized to receive clozapine and 69 randomized to receive a nonclozapine SGA. All participants underwent a change in medication as a result of randomization. In the clozapine arm, 54% remained on the assigned medication at 1 year, at a mean dose of 333 mg daily. In the SGA arm, 57% remained on an SGA at 1 year, although in 4 patients this was a different SGA from the one started initially. By chance, patients randomized to clozapine treatment had mean QLS scores at baseline that were higher (that is, better) than those in the SGA arm. Overall, the results of CUtLASS 2 suggested that patients in the clozapine arm experienced somewhat more improvement in QLS total scores, compared with the SGA arm, although this did not reach statistical significance (P < 0.08). 5
Secondary Outcomes
Efficacy Measures. In addition to antipsychotic class effects on QLS scores over the course of 1 year, CUtLASS 1 also examined various secondary outcomes. There were no differences in overall psychopathology as measured by the PANSS total score, or in positive symptoms, negative symptoms, or general psychopathology. 4 There were also no differences in depression scores between the 2 groups, GAF scores, drug attitude, or compliance.
Similar examination of secondary efficacy outcomes in CUtLASS 2 revealed a significant benefit for clozapinetreated patients over other SGAs regarding improvement in overall psychopathology (PANSS total score). 5 Further, on participant satisfaction questionnaires, greater improvement in mental health was noted after 12 weeks of treatment for patients treated with clozapine, compared with other SGAs. There were no differences between treatment groups in depression scores, GAF scores, drug attitude, or compliance.
Cost-Effectiveness. A cost-effectiveness analysis based on the results of CUtLASS 1 demonstrated a trend toward lower mean direct costs in patients allocated to the FGA arm (mean annual costs £18 858, SD £28 602), compared with those in the SGA arm (mean annual costs £20 118, SD £25 348). 6 Antipsychotic drug costs accounted for only a small proportion of total costs (2.1% in the FGA arm and 3.8% in the SGA arm). The major costs in both groups were from psychiatric hospital inpatient admissions (93.2% and 81.5% of total costs in the FGA and SGA arms, respectively). Moreover, there was no evidence to suggest that SGAs overall were more cost-effective than FGAs, with findings in fact suggesting the opposite; that is, FGAs may be associated with small cost savings and a small gain in QALYs, compared with SGAs.
In CUtLASS 2, a similar cost-effectiveness analysis did not find significant differences in total health care costs or QALYs between the clozapine and SGA groups. 7 The authors concluded that clozapine was not likely to be cost-effective within the range of willingness-to-pay values (that is, the amount health policy-makers are willing to pay to gain 1 QALY) implied by the National Institute for Health and Clinical Excellence in the United Kingdom, estimated at between £25 000 and £35 000. However, this conclusion was tempered somewhat after adjusting for the cost of mandatory inpatient admissions to initiate clozapine.
Adverse Events. In CUtLASS 1, comparing FGAs and SGAs, there were no significant differences in adverse medication effects between the 2 groups, including EPSs, akathisia, and TD. 4 Similarly, in CUtLASS 2, comparing clozapine with other SGAs, there were no significant differences between the groups in treatment-emergent adverse events, including EPSs, akathisia, TD, and weight gain. 5
The CATIE Schizophrenia Trial
Rationale
Similar to the CUtLASS, the CATIE schizophrenia trial was designed to investigate the comparative effectiveness of SGAs and FGAs, in this case the SGAs olanzapine, risperidone, quetiapine, and ziprasidone, and the FGA perphenazine, an intermediate potency representative of the FGA class of medications. The primary effectiveness measure used was discontinuation of treatment for any cause. This outcome measure was chosen because: stopping or changing medication is a frequent occurrence and major problem in the treatment of schizophrenia; and, it integrates patients' and clinicians' judgments of efficacy, safety, and tolerability into a global measure of effectiveness that reflects their evaluation of therapeutic benefits in relation to undesired effects. 8 The authors hypothesized that there would be significant differences in the overall effectiveness of antipsychotics in the treatment of schizophrenia.
Design and Methodology
The CATIE study was a multicentre, double-blind RCT carried out at 57 clinical sites in the United States. Eligible participants were aged 18 to 65 years, with a diagnosis of schizophrenia, determined by the Structured Clinical Interview of the DSM-IV, and were able to take oral antipsychotic medication. Patients were excluded based on the following: a diagnosis of schizoaffective disorder, mental retardation, or other cognitive disorder; history of serious adverse reactions to the proposed treatments; only one episode of schizophrenia; history of treatment resistance; pregnancy or breastfeeding; or, a serious and unstable medical condition.
Patients were initially randomly assigned to receive olanzapine, perphenazine, quetiapine, risperidone, or ziprasidone (after approval for use by the Food and Drug Administration) and followed for up to 18 months or until treatment was discontinued for any reason (Phase 1). Of note, patients with TD could enrol in the study but their randomization scheme prevented them from being assigned to treatment with perphenazine. Patients who were assigned to treatment in Phase 1 with perphenazine and who discontinued it then entered Phase 1B and received randomized double-blinded treatment with olanzapine, quetiapine, or risperidone. If patients discontinued the assigned treatment in Phase 1B, or discontinued treatment of an SGA in Phase 1, they were eligible for Phase 2.
In Phase 2, patients and their study doctors could choose between 2 pathways that then involved randomization. The efficacy pathway (Phase 2E) was recommended to people who discontinued previous treatment because of inefficacy, and randomized subjects in a 1:1 ratio to either open-label clozapine or double-blind treatment with another atypical antipsychotic (olanzapine, quetiapine, or risperidone). The tolerability pathway (Phase 2T) was recommended to people who discontinued the previous treatment because of intolerability, and randomized subjects to double-blind treatment with olanzapine, quetiapine, risperidone, and ziprasidone. Subjects entering Phase 2T before the availability of ziprasidone were randomized to a drug not previously received in a 1:1 ratio, while those entering after its availability were randomized in a 2:1:1 ratio to ziprasidone or to one of the other atypical antipsychotics not previously received, respectively.
As already described, the primary outcome measure was discontinuation of treatment for any cause. Secondary outcomes included the specific reasons for discontinuation of treatment (for example, inefficacy or intolerability owing to side effects such as weight gain, extrapyramidal signs, or sedation as judged by the study doctor). Additional secondary efficacy measures were scores on the PANSS and the CGI scale, composite scores on neurocognitive testing, and quality of life as measured by the QLS. Rates of employment and participation in psychosocial rehabilitation were collected throughout Phase 1. DNA was collected for genetic testing of 25 known functional variants in the major and minor metabolizing enzymes for each medication used in Phase 1. Secondary safety and tolerability outcomes included the incidence of serious adverse events, adverse events during treatment, neurologic side effects, changes in weight, laboratory measures of metabolic syndrome indices, and electrocardiographic findings. Further, direct costs including medication and health service use data were collected for cost-effectiveness analysis.
Funding
The CATIE trial was funded by the NIMH. Medications for the study were provided by the respective pharmaceutical companies. The NIMH and the study principal investigators were responsible for design and conduct of the trial, and the primary analyses. There was no industry involvement in these activities.
Primary Outcomes
Phase 1 of the CATIE schizophrenia trial consisted of a total of 1432 patients. Among these patients, 74% discontinued their treatment for any cause before 18 months: olanzapine 64%; perphenazine 75%; quetiapine 82%; risperidone 74%; and ziprasidone 79%. 8 Time to treatment discontinuation for any cause was significantly longer in the olanzapine group than the quetiapine or risperidone groups. Comparisons with perphenazine and ziprasidone groups were in the same direction, but were not statistically significant. There were no differences between groups in time to discontinuation owing to intolerable side effects. However, time to treatment discontinuation for lack of efficacy was longer in the olanzapine group than the perphenazine, quetiapine, or risperidone groups.
Phase 1B, which examined the effectiveness of olanzapine, quetiapine, and risperidone in patients who had discontinued perphenazine, consisted of 114 patients who accepted random assignment and took at least one dose of the assigned medication. In this phase, 68% discontinued treatment before completion of the study, with a median treatment duration of 5.8 months. 9 Time to treatment discontinuation for any cause was significantly longer for quetiapine and olanzapine, compared with risperidone, with no significant differences between the former 2. There were no treatment group differences in specific cause for treatment discontinuation (that is, lack of efficacy, intolerable side effects, or patient decision).
Phase 2T examined the effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients who had discontinued a previous SGA, and consisted of 444 patients. In this phase, treatment discontinuation for any cause occurred in 64% to 84% of patients (olanzapine 67%; quetiapine 84%; risperidone 64%; and ziprasidone 77%). 10 Time to any cause treatment discontinuation was significantly longer for olanzapine and risperidone, compared with quetiapine and ziprasidone. Further, there was an overall treatment group difference in time to treatment discontinuation owing to lack of efficacy, but no group comparisons were statistically significant after adjusting for multiple comparisons. There were no overall group differences in time to treatment discontinuation owing to intolerable side effects. In examining effectiveness outcomes based on reasons for prior treatment discontinuation, olanzapine exhibited an advantage (that is, longer time to treatment discontinuation) in patients who discontinued their previous treatment owing to lack of efficacy, compared with quetiapine and ziprasidone, but not risperidone.
Phase 2E examined the effectiveness of clozapine, compared with olanzapine, quetiapine, and risperidone, in patients who had discontinued previous SGA treatment, and consisted of 99 patients. In this phase of the CATIE trial, 69% of patients discontinued treatment for any cause before completion of the study: clozapine 56%; olanzapine 71%; quetiapine 93%; and risperidone 86%. 11 Effectiveness of clozapine was found to be significantly superior to quetiapine and risperidone, but not olanzapine. Median times to all-cause treatment discontinuation were 10.5 months for clozapine, 2.7 months for olanzapine, 3.3 months for quetiapine, and 2.8 months for risperidone. In patients who discontinued treatment owing to lack of efficacy, clozapine was significantly superior to all 3 other medications. There were no differences between treatments in time to discontinuation owing to intolerable side effects or patient decision.
Secondary Outcomes
Efficacy Measures. In Phases 1 and 1B of the CATIE study there were improvements in total PANSS scores over time in all groups, with no significant differences between treatment groups. 8, 9 This was also the case for CGI scores across groups. In Phase 2T, the olanzapine group showed greater improvement on total PANSS scores, compared with the quetiapine and ziprasidone groups, but not the risperidone group. 10 Similar results were found for improvement in PANSS positive symptom scores. However, there were no treatment differences for PANSS negative scores, and no treatment group differences for change in CGI severity ratings. In Phase 2E, after 3 months of treatment, clozapine-treated patients exhibited greater improvement in PANSS total score, compared with quetiapine or risperidone, but not olanzapine. 11 Further, the clozapine group exhibited significantly greater reductions in CGI severity scores, compared with the olanzapine and quetiapine groups.
Metabolic Side Effects. More patients in Phase 1 discontinued treatment with olanzapine owing to weight gain or metabolic effects, and olanzapine treatment was associated with significantly more weight gain, compared with treatment with other medications, with an average weight gain of 2 pounds (0.9 kg) per month. 8 Olanzapine was also associated with greater increases in glycosylated hemoglobin, total cholesterol, and triglycerides. Similar results were noted in Phase 1B and Phase 2T, with average weight gain of 1.6 and 1.3 pounds per month, respectively. 9, 10 In Phase 2E there were no significant group differences in metabolic measures. 11 An evaluation of propensity for the development of the metabolic syndrome by antipsychotic use over the first 3 months in Phase 1 of the CATIE trial was carried out by Meyer et al. 12 Within 3 months of exposure to olanzapine, there was a significant increase in the proportion of subjects who met metabolic syndrome criteria (9.1% over baseline rates), whereas subjects switched to ziprasidone showed a decreased prevalence of metabolic syndrome (-7.8% from baseline rates). Further, olanzapine and quetiapine were both associated with the largest increases in patients' waist circumference. There were no significant differences between treatment groups in average changes in blood pressure, high density lipoproteins, and fasting glucose. Additionally, olanzapine and quetiapine-treated patients exhibited the greatest increases in mean nonfasting triglyceride levels, while patients treated with the other antipsychotics either showed no increase (ziprasidone) or a decrease (risperidone and perphenazine). 13 Using the Framingham risk equation, Daumit et al 14 evaluated the differential impact of antipsychotics in Phase 1 of the CATIE trial on 10-year CHD risk. They found olanzapine and quetiapine treatment to be associated with increased CHD risk, whereas risk decreased for patients treated with perphenazine, risperidone, and ziprasidone. Patients who were particularly susceptible to such increased CHD risks already had at least a 10% baseline CHD risk, aged 40 years or younger, or aged 49 years or older, and male patients.
Neurologic Side Effects. In Phase 1, more patients discontinued perphenazine owing to subjectively reported extrapyramidal side effects. 8 However, objective measures of neurologic side effects, including the Simpson-Angus Rating Scale for EPSs, the Barnes Akathisia Scale, and the AIMS for TD, demonstrated no significant differences among treatment groups in the incidence of extrapyramidal side effects, akathisia, or TD. 8, 15 Similarly, in Phase 2T of the CATIE trial, there were no differences between treatment groups in any neurologic side effects. 10 Other Adverse Events. Throughout all phases of the CATIE trial, risperidone was the only antipsychotic associated with a substantial increase in prolactin levels. [8] [9] [10] [11] There were no significant differences between antipsychotics on the corrected QT interval, and torsades de pointes did not develop in any patient. There were also no differences between groups in the incidence of new cataracts.
Neurocognitive Outcomes. Phase 1 of the CATIE trial also examined the differential impact of antipsychotic medications on neurocognitive functioning, with the primary focus on changes over the first 2 months of treatment. Overall, all treatment groups demonstrated slight but statistically significant improvement on a neurocognitive composite score, with small improvements primarily in the domains of processing speed, reasoning, working memory, and vigilance. There were no differences between treatment groups in composite or individual component scores after the first 2 months of treatment. 16 Exploratory analysis of neurocognitive functioning for subjects completing 18 months of treatment on the initially assigned medication suggested greater improvement in patients treated with perphenazine than olanzapine (P = 0.002) or risperidone (P = 0.04). Neurocognitive improvement in the ziprasidone and quetiapine groups did not differ from other treatment groups.
Functional Outcomes. Examination of the impact of antipsychotics on quality of life, as measured by the QLS, in Phase 1 of the CATIE trial revealed small but significant improvements across treatment groups, particularly for patients with lower baseline QLS scores. Secondary examination of changes in subscales of the QLS revealed some significant improvements in interpersonal relations in patients treated with olanzapine and risperidone, and in instrumental role functioning in those treated with perphenazine and quetiapine. However, there was no clear superiority of any antipsychotic in improving psychosocial functioning. 17 This was also the case for patients treated with clozapine in Phase 2E, who exhibited comparable improvement in psychosocial functioning. Examination of the differential impact of antipsychotics on employment and participation in psychosocial rehabilitation did not find superiority for any of the antipsychotics in Phase 1 of the trial for either measure. 18 
Impact of Baseline Medication
Status. An examination of staying, compared with switching, in Phase 1 of the CATIE trial compared all-cause treatment discontinuation for patients whose random assignment resulted in staying with the same antipsychotic they were already receiving at baseline, compared with switching to a different one, and examined the impact of excluding patients that stayed on previous treatment on discontinuation rates observed in Phase 1. This analysis demonstrated significantly longer times to treatment discontinuation for patients in the olanzapine and risperidone groups who were taking the same antipsychotic prior to randomization, compared with those who were switched from another antipsychotic. 19 Following exclusion of these so-called stayers, reanalysis of the original Phase 1 data revealed attenuation of the advantage seen in the olanzapinetreated patients regarding time to all-cause treatment discontinuation, and the disappearance of significant overall treatment group differences.
Cost-Effectiveness. An analysis of cost-effectiveness based on initial treatment group, including any antipsychotic medications used in subsequent phases of the patients' progress through the CATIE trial, was also performed and involved data on 1424 patients. This analysis demonstrated significantly lower total health care costs for patients in the perphenazine group, compared with the atypical antipsychotics, with lower average monthly costs of US$300 to US$600 (20% to 30%). 20 20 Perphenazine was associated with better QALY ratings than other agents, although this was only significant compared with risperidone.
Genetic Determinants of Drug Metabolism. Grossman et al 21 examined the contributions of 25 known functional genetic variants in the major and minor drug metabolizing enzymes for each medication in Phase 1 of the CATIE trial. They did not find any strong associations between the relevant genetic variants and the safety or efficacy of antipsychotic medications, or with their optimized doses.
Impact of Illicit Substance Use. Swartz et al 22 re-evaluated the results of the CATIE Phase 1 trial in an effort to determine the impact illicit substance use had on discontinuation rates from the different antipsychotic medications. Among patients not using illicit substances at baseline, discontinuation rate was lower and time to all-cause treatment discontinuation was longer for those treated with olanzapine, compared with quetiapine, risperidone, and perphenazine, but not ziprasidone. However, among patients using illicit substances at baseline, discontinuation rates and time to all-cause treatment discontinuation was not different between any of the treatment groups. Further, there were no treatment group difference on secondary efficacy measures (PANSS and CGI) between substance users and nonusers. Rates of medication compliance were found to be higher for nonusers, but with no differences across treatment groups. Of note, alcohol use and abuse in the absence of illicit substance use had no impact on time to treatment discontinuation.
Antipsychotic Medication Effects on
Violence. An examination of the impact antipsychotic medications have on rates of violence in people with schizophrenia in Phase 1 of the CATIE trial was conducted using the MacArthur Community Violence Interview. 23 The analysis combined minor violence (battery without injury or weapon use) and serious violence (any battery using a weapon or resulting in injury, any threat with a lethal weapon in hand, or any sexual assault), owing to very low base rates of serious violence. Overall, there was evidence of a decline in rate of violence, from 16% to 9% in the retained sample and 19% to 14% in the intention-to-treat sample. There were no significant treatment group differences. Further, antipsychotic medication adherence across all treatment groups was found to significantly reduce violence, although only in patients without a history of childhood conduct problems.
Discussion
As the prototype of atypicality, clozapine fostered a new class of antipsychotics that began entering clinical practice in the mid-1990s. These SGAs breathed new life into the field of schizophrenia, where pharmacotherapy had long been established as the cornerstone of treatment programs. Clinicians were all too aware of the limitations of FGAs, yet there had been no significant advances for almost 4 decades. Numerous efficacy trials, undertaken for regulatory approval, offered compelling evidence that these newer antipsychotics were more effective, broader in clinical scope (that is, with beneficial effects on negative and cognitive symptoms), and without the EPS burden that was pervasive amongst FGAs. A kind of therapeutic nihilism gave way to hope that affected both clinical practice and research alike-one cannot underestimate the gains the field has made as a result of this injection of newfound optimism.
As is practice, though, smaller well-controlled efficacy trials gave way to larger naturalistic studies that might confirm the earlier results in a real-world setting. We now have 2 large independent effectiveness trials, CUtLASS and CATIE, that serve to temper the initial enthusiasm. Collectively, results of these trials suggest that SGAs are roughly equivalent to FGAs regarding effectiveness in the treatment of schizophrenia. The one exception is clozapine, which exhibits some superiority both in overall effectiveness and in improvement in psychopathology in people resistant to treatment with other antipsychotics. Among the nonclozapine SGAs, olanzapine seems to stand out somewhat regarding effectiveness, although this benefit in the context of the CATIE trial may have been largely dependent on patients who remained on olanzapine after entry into the study (that is, the stayers). Both trials demonstrated equivalence between SGAs and FGAs in the treatment of negative symptoms. Further, there was no evidence to suggest distinct benefit for any antipsychotic in neurocognitive or psychosocial functioning. Concurrent substance use adversely affected medication compliance, although alcohol use and abuse in the absence of illicit substance use did not appear to impact time to treatment discontinuation.
From the standpoint of side effects, a major claim for the SGAs has been a reduced burden, particularly regarding neurologic side effects. Once again, the effectiveness data temper such claims, as the results of both CUtLASS and CATIE clearly demonstrate that, at appropriate doses of FGAs, there is no significant difference between the 2 classes of medications in neurologic side effects. In addition, what has emerged more recently, and is confirmed by both of these trials, is that olanzapine stands out as a significant culprit in metabolic side effects and increasing Framingham CHD risk. This is also true for quetiapine treatment, which showed similar associations.
For the treating clinicians, what are the take-home messages? First, we are forced to acknowledge that choice of antipsychotic is (as it was when we had only FGAs) guided largely by side effects. Second, we have yet further evidence that clozapine is unique in the refractory population, and attempts to sidestep its use because it is more cumbersome than other antipsychotics is to offer substandard care to people who are treatment resistant. Third, we are provided evidence that the therapeutic challenge is finding the right antipsychotic, although just as important is keeping the patient on that treatment over time. This may well account for why longer-term data looking at clozapine find that its superiority is more elusive when the comparison group represents people who have remained on an antipsychotic, whatever it might be. [24] [25] [26] Finally, we are given a clear signal that putting all our eggs in the medication basket, with hopes of eradicating symptoms, may be misguided. It is patently clear that at least for now, medication provides but one part of a story that must be complemented by nonpharmacological strategies that speak to more functionally relevant outcome measures.
Most of all, we are reminded that we still understand very little about this illness, a good reason to challenge notions that appear to be written in stone.
Résumé : Antipsychotiques et schizophrénie : de l'efficacité potentielle et réelle à la prise de décisions cliniques
Objectif : Examiner complètement les 2 vastes essais récents sur l'efficacité des antipsychotiques pour le traitement de la schizophrénie : l'étude du Royaume-Uni sur le rapport coût-efficacité des antipsychotiques les plus récents pour la schizophrénie (CUtLASS), et l'étude du National Institute of Mental Health d'essais cliniques sur l'efficacité des traitements aux antipsychotiques (CATIE) dans la schizophrénie.
Méthode : Nous présentons une revue de la raison d'être, de la méthodologie, et des résultats à ce jour des essais CUtLASS et CATIE sur la schizophrénie, y compris toutes les issues primaires et secondaires. 
Résultats
